

Jerome Robert

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6883568/publications.pdf>

Version: 2024-02-01

173
papers

9,648
citations

44069

48
h-index

39675

94
g-index

201
all docs

201
docs citations

201
times ranked

8594
citing authors

#	ARTICLE	IF	CITATIONS
1	Surging bloodstream infections and antimicrobial resistance during the first wave of COVID-19: a study in a large multihospital institution in the Paris region. <i>International Journal of Infectious Diseases</i> , 2022, 114, 90-96.	3.3	28
2	Association of Healthcare and Aesthetic Procedures with Infections Caused by Nontuberculous Mycobacteria, France, 2012-2020. <i>Emerging Infectious Diseases</i> , 2022, 28, 518-526.	4.3	10
3	Molecular detection of isoniazid monoresistance improves tuberculosis treatment: A retrospective cohort in France. <i>Journal of Infection</i> , 2022, 85, 24-30.	3.3	4
4	Ciprofloxacin population pharmacokinetics during long-term treatment of osteoarticular infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2906-2913.	3.0	5
5	Susceptibility Testing Is Key for the Success of Cefiderocol Treatment: A Retrospective Cohort Study. <i>Microorganisms</i> , 2021, 9, 282.	3.6	28
6	Efficacy of aztreonam with β -lactamase inhibitors against metallo-carbapenemase-producing Enterobacteria. <i>Infectious Diseases Now</i> , 2021, 51, 639-640.	1.6	0
7	Impact of the revised definition of extensively drug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2021, 58, 2100641.	6.7	5
8	<i>Mycobacterium chimaera</i> Genomics With Regard to Epidemiological and Clinical Investigations Conducted for an Open Chest Postsurgical <i>Mycobacterium chimaera</i> Infection Outbreak. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab192.	0.9	5
9	Sampling strategy for bacteriological diagnosis of intrathoracic tuberculosis. <i>Respiratory Medicine and Research</i> , 2021, 79, 100825.	0.6	2
10	Isoniazid-monoresistant tuberculosis in France: Risk factors, treatment outcomes and adverse events. <i>International Journal of Infectious Diseases</i> , 2021, 107, 86-91.	3.3	11
11	Rapid Molecular Diagnosis of Tuberculosis and Its Resistance to Rifampicin and Isoniazid with Automated MDR/MTB ELITE MGBA® Assay. <i>Antibiotics</i> , 2021, 10, 797.	3.7	1
12	Impact of stewardship strategy on antibiotic use in <i>Clostridoides difficile</i> infection. <i>Infectious Diseases Now</i> , 2021, 51, 499-501.	1.6	0
13	Controlling healthcare-associated transmission of SARS-CoV-2 variant of concern 202012/01 in a large hospital network. <i>Journal of Hospital Infection</i> , 2021, 114, 182-184.	2.9	4
14	Clinical, epidemiological and therapeutic characteristics of <i>Mycoplasma genitalium</i> infection in a French STI center. <i>Infectious Diseases Now</i> , 2021, , .	1.6	2
15	<i>Clostridoides difficile</i> Infection Rates after Ceftolozane-Tazobactam and Ceftazidime-Avibactam Treatment Compared to Carbapenem Treatment: A Retrospective Single-Center Study. <i>Hygiene</i> , 2021, 1, 99-105.	1.7	0
16	A Comprehensive Evaluation of GeneLEAD VIII DNA Platform Combined to Deeplex Myc-TBA® Assay to Detect in 8 Days Drug Resistance to 13 Antituberculous Drugs and Transmission of <i>Mycobacterium tuberculosis</i> Complex Directly From Clinical Samples. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 707244.	3.9	14
17	<i>Corynebacterium striatum</i> thrombophlebitis: a nosocomial multidrug-resistant disease?. <i>Access Microbiology</i> , 2021, 3, 000307.	0.5	2
18	Neurological diseases of unknown etiology: Brain-biopsy diagnostic yields and safety. <i>European Journal of Internal Medicine</i> , 2020, 80, 78-85.	2.2	18

#	ARTICLE	IF	CITATIONS
19	Bedaquiline and delamanid for drug-resistant tuberculosis: a clinician's perspective. <i>Future Microbiology</i> , 2020, 15, 779-799.	2.0	11
20	Do Contact Precautions Reduce the Incidence of Intensive Care Unit-Acquired Pseudomonas aeruginosa Infections? The DPCPYO (Detection and Contact Precautions for Patients With P.) Trial. <i>Clinical Infectious Diseases</i> , 2020, 70, 1010-1017.	10.7	697
21	Telacebec (Q203)-containing intermittent oral regimens sterilized mice infected with Mycobacterium ulcerans after only 16 doses. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0007857.	3.0	10
22	Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial. <i>Lancet</i> , The, 2020, 395, 1259-1267.	13.7	71
23	Rational Choice of Antibiotics and Media for Mycobacterium avium Complex Drug Susceptibility Testing. <i>Frontiers in Microbiology</i> , 2020, 11, 81.	3.5	9
24	Combining bacteriophages and dalbavancin for salvage therapy of complex Staphylococcus aureus extradural empyema. <i>Medicine (Baltimore)</i> , 2020, 99, e202001.	5.0	4
25	Usefulness of point-of-care multiplex PCR to rapidly identify pathogens responsible for ventilator-associated pneumonia and their resistance to antibiotics: an observational study. <i>Critical Care</i> , 2020, 24, 378.	5.8	22
26	Validation of the Bacterial Meningitis Score in adults consulting at an emergency department: a retrospective multicentric study. <i>European Journal of Emergency Medicine</i> , 2020, 27, 447-453.	1.1	2
27	Ventilator-associated pneumonia in patients with SARS-CoV-2-associated acute respiratory distress syndrome requiring ECMO: a retrospective cohort study. <i>Annals of Intensive Care</i> , 2020, 10, 158.	4.6	108
28	359. Ventilator-associated pneumonia in patients with SARS-CoV-2-associated acute respiratory failure requiring mechanical ventilation: a retrospective cohort study. <i>Open Forum Infectious Diseases</i> , 2020, 7, S249-S250.	0.9	0
29	Title is missing!. , 2020, 14, e0007857.		0
30	Title is missing!. , 2020, 14, e0007857.		0
31	Title is missing!. , 2020, 14, e0007857.		0
32	Title is missing!. , 2020, 14, e0007857.		0
33	Title is missing!. , 2020, 14, e0007857.		0
34	Title is missing!. , 2020, 14, e0007857.		0
35	A nationwide survey on involvement of clinical microbiologists in antibiotic stewardship programmes in large French hospitals. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2019, 38, 2235-2241.	2.9	1
36	<i>Erwinia billingiae</i> as Unusual Cause of Septic Arthritis, France, 2017. <i>Emerging Infectious Diseases</i> , 2019, 25, 1587-1589.	4.3	5

#	ARTICLE	IF	CITATIONS
37	Trends and prediction of antimicrobial susceptibility in urinary bacteria isolated in European emergency departments: the EuroUTI 2010-2016 Study. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 3069-3076.	3.0	9
38	Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis. <i>Emerging Infectious Diseases</i> , 2019, 25, 936-943.	4.3	68
39	Multidisciplinary advisory teams to manage multidrug-resistant tuberculosis: the example of the French Consilium. <i>International Journal of Tuberculosis and Lung Disease</i> , 2019, 23, 1050-1054.	1.2	10
40	Awareness among French healthcare workers of the transmission of multidrug resistant organisms: a large cross-sectional survey. <i>Antimicrobial Resistance and Infection Control</i> , 2019, 8, 173.	4.1	6
41	Risk factors for carbapenem-resistant Enterobacteriaceae infections: a French case-control-control study. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2019, 38, 383-393.	2.9	31
42	Poor Performance of Rapid Molecular Tests to Define Eligibility for the Shortcourse Multidrug-resistant Tuberculosis Regimen. <i>Clinical Infectious Diseases</i> , 2019, 68, 1410-1411.	5.8	2
43	Molecular epidemiology of <i>Pseudomonas aeruginosa</i> isolated from infected ICU patients: a French multicenter 2012-2013 study. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2019, 38, 921-926.	2.9	18
44	Trimethoprim susceptibility in <i>E. coli</i> community-acquired urinary tract infections in France. <i>Médecine Et Maladies Infectieuses</i> , 2018, 48, 410-413.	5.0	7
45	A cluster of multidrug-resistant <i>Mycobacterium tuberculosis</i> among patients arriving in Europe from the Horn of Africa: a molecular epidemiological study. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 431-440.	9.1	121
46	Safety and efficacy of exposure to bedaquiline-delamanid in multidrug-resistant tuberculosis: a case series from France and Latvia. <i>European Respiratory Journal</i> , 2018, 51, 1702550.	6.7	30
47	Surveillance for control of antimicrobial resistance. <i>Lancet Infectious Diseases</i> , The, 2018, 18, e99-e106.	9.1	235
48	Comparison of methods available for identification of <i>Mycobacterium chimaera</i> . <i>Clinical Microbiology and Infection</i> , 2018, 24, 409-413.	6.0	34
49	Management and outcome of bloodstream infections: a prospective survey in 121 French hospitals (SPA-BACT survey). <i>Infection and Drug Resistance</i> , 2018, Volume 11, 1359-1368.	2.7	21
50	Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. <i>Lancet</i> , The, 2018, 392, 821-834.	13.7	452
51	Risk factors for extensive drug resistance in multidrug-resistant tuberculosis cases: a case-case study. <i>International Journal of Tuberculosis and Lung Disease</i> , 2018, 22, 54-59.	1.2	12
52	Clinical management of respiratory syndrome in patients hospitalized for suspected Middle East respiratory syndrome coronavirus infection in the Paris area from 2013 to 2016. <i>BMC Infectious Diseases</i> , 2018, 18, 331.	2.9	27
53	<i>Bacillus cereus</i> , a serious cause of nosocomial infections: Epidemiologic and genetic survey. <i>PLoS ONE</i> , 2018, 13, e0194346.	2.5	99
54	Efficiency of different control measures for preventing carbapenemase-producing enterobacteria and glycopeptide-resistant <i>Enterococcus faecium</i> outbreaks: a 6-year prospective study in a French multihospital institution, January 2010 to December 2015. <i>Eurosurveillance</i> , 2018, 23, .	7.0	18

#	ARTICLE	IF	CITATIONS
55	Application of guidelines for aminoglycosides use in French hospitals in 2013–2014. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2017, 36, 1083-1090.	2.9	8
56	Multidrug and extensively drug-resistant tuberculosis. <i>Médecine Et Maladies Infectieuses</i> , 2017, 47, 3-10.	5.0	26
57	Rapid emergence of <i>Mycobacterium tuberculosis</i> bedaquiline resistance: lessons to avoid repeating past errors. <i>European Respiratory Journal</i> , 2017, 49, 1601719.	6.7	86
58	Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2017, 49, 1601799.	6.7	112
59	Molecular detection methods of resistance to antituberculosis drugs in <i>Mycobacterium tuberculosis</i> . <i>Médecine Et Maladies Infectieuses</i> , 2017, 47, 340-348.	5.0	11
60	Reply: Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 1489-1490.	5.6	2
61	Development of an algorithm for phenotypic screening of carbapenemase-producing Enterobacteriaceae in the routine laboratory. <i>BMC Infectious Diseases</i> , 2017, 17, 78.	2.9	12
62	Propensity Score-Based Approaches to Confounding by Indication in Individual Patient Data Meta-Analysis: Non-Standardized Treatment for Multidrug Resistant Tuberculosis. <i>PLoS ONE</i> , 2016, 11, e0151724.	2.5	12
63	Multidrug-resistant bacteria transmitted through high-density EEG in ICU. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2016, 37, 65-68.	2.0	2
64	Performance of the New Version (v2.0) of the GenoType MTBDR Test for Detection of Resistance to Second-Line Drugs in Multidrug-Resistant <i>Mycobacterium tuberculosis</i> Complex Strains. <i>Journal of Clinical Microbiology</i> , 2016, 54, 1573-1580.	3.9	46
65	In vivo <i>Mycobacterium tuberculosis</i> fluoroquinolone resistance emergence: a complex phenomenon poorly detected by current diagnostic tests. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3465-3472.	3.0	9
66	Limited Benefit of the New Shorter Multidrug-Resistant Tuberculosis Regimen in Europe. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 1029-1031.	5.6	71
67	Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis?. <i>European Respiratory Journal</i> , 2016, 48, 582-585.	6.7	19
68	<i>qnrA6</i> genetic environment and quinolone resistance conferred on <i>Proteus mirabilis</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 903-908.	3.0	4
69	Surgery as an Adjunctive Treatment for Multidrug-Resistant Tuberculosis: An Individual Patient Data Metaanalysis. <i>Clinical Infectious Diseases</i> , 2016, 62, 887-895.	5.8	64
70	XDR-tuberculosis in France: Community transmission due to non-compliance with isolation precautions. <i>Médecine Et Maladies Infectieuses</i> , 2016, 46, 52-55.	5.0	11
71	Tenofovir DF/emtricitabine and efavirenz combination therapy for HIV infection in patients treated for tuberculosis: the ANRS 129 BKVIR trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 783-793.	3.0	2
72	Prevalence of extended-spectrum beta-lactamase producing <i>Escherichia coli</i> in community-onset urinary tract infections in France in 2013. <i>Journal of Infection</i> , 2016, 72, 201-206.	3.3	42

#	ARTICLE	IF	CITATIONS
73	Sterilizing Activity of Fully Oral Intermittent Regimens against Mycobacterium Ulcerans Infection in Mice. PLoS Neglected Tropical Diseases, 2016, 10, e0005066.	3.0	23
74	Antibiotic use and good practice in 314 French hospitals: The 2010 SPA2 prevalence study. Médecine Et Maladies Infectieuses, 2015, 45, 475-480.	5.0	14
75	Survey of French physician practices in treatment and control of transmission of smear-positive tuberculosis. International Journal of Tuberculosis and Lung Disease, 2015, 19, 205-209.	1.2	5
76	High Rate of Multidrug-Resistant Gram-Negative Bacilli Carriage and Infection in Hospitalized Returning Travelers: a Cross-Sectional Cohort Study. Journal of Travel Medicine, 2015, 22, 292-299.	3.0	48
77	Molecular Diagnosis of Fluoroquinolone Resistance in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 2015, 59, 1519-1524.	3.2	35
78	Bedaquiline: de l'in vitro aux essais cliniques d'un nouvel antituberculeux. Journal Des Anti-infectieux, 2015, 17, 60-66.	0.1	1
79	Detection of OXA-48-like carbapenemase genes by the Xpert® Carba-R test: room for improvement. International Journal of Antimicrobial Agents, 2015, 45, 441-442.	2.5	25
80	Elaboration of a consensual definition of de-escalation allowing a ranking of β-lactams. Clinical Microbiology and Infection, 2015, 21, 649.e1-649.e10.	6.0	112
81	Assessing Primary and Secondary Resistance to Clarithromycin and Amikacin in Infections Due to Mycobacterium avium Complex. Antimicrobial Agents and Chemotherapy, 2015, 59, 7153-7155.	3.2	10
82	First multicenter study on multidrug resistant bacteria carriage in Chinese ICUs. BMC Infectious Diseases, 2015, 15, 358.	2.9	26
83	Corrigendum to "Elaboration of a consensual definition of de-escalation allowing a ranking of β-lactams" [Clin Microbiol Infec 21 (2015) 649.e1-649.e10]. Clinical Microbiology and Infection, 2015, 21, 6.0 e81.	6.0	1
84	Carbapenem use in French hospitals: A nationwide survey at the patient level. International Journal of Antimicrobial Agents, 2015, 46, 707-712.	2.5	23
85	Treatment outcomes for HIV and MDR-TB co-infected adults and children: systematic review and meta-analysis. International Journal of Tuberculosis and Lung Disease, 2015, 19, 969-978.	1.2	99
86	Compassionate Use of Bedaquiline for the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: Interim Analysis of a French Cohort. Clinical Infectious Diseases, 2015, 60, 188-194.	5.8	165
87	Impact of the BCG vaccination policy on tuberculous meningitis in children under 6 years in metropolitan France between 2000 and 2011. Eurosurveillance, 2015, 20, .	7.0	10
88	First report of the predominance of clonal complex 398 Staphylococcus aureus strains in osteomyelitis complicating diabetic foot ulcers: a national French study. Clinical Microbiology and Infection, 2014, 20, O274-O277.	6.0	28
89	Significant Difference in Drug Susceptibility Distribution between Mycobacterium avium and Mycobacterium intracellulare. Journal of Clinical Microbiology, 2014, 52, 4439-4440.	3.9	15
90	Rifampicin mono-resistant tuberculosis in France: a 2005-2010 retrospective cohort analysis. BMC Infectious Diseases, 2014, 14, 18.	2.9	22

#	ARTICLE	IF	CITATIONS
91	Treatment Outcomes of Patients With Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis According to Drug Susceptibility Testing to First- and Second-line Drugs: An Individual Patient Data Meta-analysis. <i>Clinical Infectious Diseases</i> , 2014, 59, 1364-1374.	5.8	116
92	<i>Pseudomonas aeruginosa</i> in French hospitals between 2001 and 2011: back to susceptibility. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2014, 33, 1713-1717.	2.9	13
93	Incidence rates of carbapenemase-producing Enterobacteriaceae clinical isolates in France: a prospective nationwide study in 2011-12. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2706-2712.	3.0	51
94	Molecular epidemiology of OXA-48-producing <i>Klebsiella pneumoniae</i> in France. <i>Clinical Microbiology and Infection</i> , 2014, 20, O1121-O1123.	6.0	51
95	Decrease in the incidence of culture-positive meningitis and cerebral tuberculomas in France from 1990 to 2007. <i>Epidemiology and Infection</i> , 2014, 142, 1510-1516.	2.1	1
96	Long-term control of carbapenemase-producing Enterobacteriaceae at the scale of a large French multihospital institution: a nine-year experience, France, 2004 to 2012. <i>Eurosurveillance</i> , 2014, 19, .	7.0	44
97	Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. <i>European Respiratory Journal</i> , 2013, 42, 169-179.	6.7	226
98	Assessment of Organizational Measures to Prevent Nosocomial Tuberculosis in Health Facilities of 4 Sub-Saharan Countries in 2010. <i>Infection Control and Hospital Epidemiology</i> , 2013, 34, 190-194.	1.8	13
99	Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. <i>European Respiratory Journal</i> , 2013, 42, 156-168.	6.7	346
100	Different Factors Associated with CTX-M-Producing ST131 and Non-ST131 <i>Escherichia coli</i> Clinical Isolates. <i>PLoS ONE</i> , 2013, 8, e72191.	2.5	20
101	A surge of MDR and XDR tuberculosis in France among patients born in the Former Soviet Union. <i>Eurosurveillance</i> , 2013, 18, 20555.	7.0	37
102	Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients. <i>PLoS Medicine</i> , 2012, 9, e1001300.	8.4	430
103	Distinguishing Colonization From Infection With <i>Staphylococcus aureus</i> in Diabetic Foot Ulcers With Miniaturized Oligonucleotide Arrays. <i>Diabetes Care</i> , 2012, 35, 617-623.	8.6	41
104	Point prevalence survey of antibiotic use in French hospitals in 2009. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 1020-1026.	3.0	59
105	Efficacy of High-dose Nebulized Colistin in Ventilator-associated Pneumonia Caused by Multidrug-resistant <i>Pseudomonas aeruginosa</i> and <i>Acinetobacter baumannii</i> . <i>Anesthesiology</i> , 2012, 117, 1335-1347.	2.5	177
106	Aerosolized Antibiotics for Ventilator-associated Pneumonia. <i>Anesthesiology</i> , 2012, 117, 1364-1380.	2.5	87
107	Impact of a 14-year screening programme on tuberculosis transmission among the homeless in Paris. <i>International Journal of Tuberculosis and Lung Disease</i> , 2012, 16, 649-655.	1.2	17
108	Link Between Carbapenemase-Producing Enterobacteria Carriage and Cross-Border Exchanges: Eight-Year Surveillance in a Large French Multihospitals Institution. <i>Journal of Travel Medicine</i> , 2012, 19, 320-323.	3.0	24

#	ARTICLE	IF	CITATIONS
109	Increase in primary drug resistance of <i>Mycobacterium tuberculosis</i> in younger birth cohorts in France. <i>Journal of Infection</i> , 2012, 64, 589-595.	3.3	9
110	Twenty years of antimicrobial resistance control programme in a regional multi hospital institution, with focus on emerging bacteria (VRE and CPE). <i>Antimicrobial Resistance and Infection Control</i> , 2012, 1, 9.	4.1	35
111	Patient's Origin and Lifestyle Associated with CTX-M-Producing <i>Escherichia coli</i> : A Case-Control-Control Study. <i>PLoS ONE</i> , 2012, 7, e30498.	2.5	36
112	Long-term control of vancomycin-resistant <i>Enterococcus faecium</i> at the scale of a large multihospital institution: a seven-year experience. <i>Eurosurveillance</i> , 2012, 17, .	7.0	30
113	Comparison of Nine Phenotypic Methods for Detection of Extended-Spectrum β -Lactamase Production by Enterobacteriaceae. <i>Journal of Clinical Microbiology</i> , 2011, 49, 1048-1057.	3.9	123
114	Multidrug-Resistant <i>Acinetobacter baumannii</i> Infections in Three Returning Travelers Evacuated From Algeria, Thailand, and Turkey After Hospitalization in Local Intensive Care Units. <i>Journal of Travel Medicine</i> , 2011, 18, 358-360.	3.0	6
115	Low carriage of vancomycin-resistant enterococci in the digestive tract of French hospitalised patients: a nationwide prospective study in 2006. <i>Journal of Hospital Infection</i> , 2011, 77, 179-181.	2.9	5
116	Nebulized Ceftazidime and Amikacin in Ventilator-associated Pneumonia Caused by <i>Pseudomonas aeruginosa</i> . <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 184, 106-115.	5.6	183
117	Panton-Valentine Leukocidin-Positive and Toxic Shock Syndrome Toxin 1-Positive Methicillin-Resistant <i>Staphylococcus aureus</i> : a French Multicenter Prospective Study in 2008. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 1734-1739.	3.2	45
118	Curbing Methicillin-Resistant <i>Staphylococcus aureus</i> in 38 French Hospitals Through a 15-Year Institutional Control Program. <i>Archives of Internal Medicine</i> , 2010, 170, 552.	3.8	138
119	Nationwide Investigation of Extended-Spectrum β -Lactamases, Metallo- β -Lactamases, and Extended-Spectrum Oxacillinases Produced by Ceftazidime-Resistant <i>Pseudomonas aeruginosa</i> Strains in France. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 3512-3515.	3.2	56
120	Effect of Catheter-Lock Solutions on Catheter-Related Infection and Inflammatory Syndrome in Hemodialysis Patients: Heparin versus Citrate 46% versus Heparin/Gentamicin. <i>Blood Purification</i> , 2010, 29, 268-273.	1.8	29
121	Impacts of Dosing Frequency of the Combination Rifampin-Streptomycin on Its Bactericidal and Sterilizing Activities against <i>Mycobacterium ulcerans</i> in Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 2955-2959.	3.2	6
122	Nationwide survey of extended-spectrum β -lactamase-producing Enterobacteriaceae in the French community setting. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 63, 1205-1214.	3.0	103
123	Carriage of Methicillin-Resistant <i>Staphylococcus aureus</i> in Home Care Settings. <i>Archives of Internal Medicine</i> , 2009, 169, 1372.	3.8	63
124	Rapid Curbing of a Vancomycin-Resistant <i>Enterococcus faecium</i> Outbreak in a Nephrology Department. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 1559-1564.	4.5	19
125	Increase in hospital-acquired bloodstream infections caused by extended spectrum β -lactamase-producing <i>Escherichia coli</i> in a large French teaching hospital. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2009, 28, 491-498.	2.9	24
126	Systematic Microbiological Tests in Kidney Transplantation and Their Value in Predicting Posttransplantation Infection. <i>Transplantation Proceedings</i> , 2009, 41, 666-668.	0.6	1

#	ARTICLE	IF	CITATIONS
127	Extended-spectrum β -lactamases in long-term-care facilities. <i>Clinical Microbiology and Infection</i> , 2008, 14, 111-116.	6.0	43
128	Bactericidal and Sterilizing Activities of Several Orally Administered Combined Regimens against <i>Mycobacterium ulcerans</i> in Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 1912-1916.	3.2	31
129	Evaluation of data quality in a laboratory-based surveillance of <i>M. tuberculosis</i> drug resistance and impact on the prevalence of resistance: France, 2004. <i>Epidemiology and Infection</i> , 2008, 136, 1172-1178.	2.1	2
130	Curing <i>Mycobacterium ulcerans</i> Infection in Mice with a Combination of Rifampin-Streptomycin or Rifampin-Amikacin. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 645-650.	3.2	23
131	A 10-year prospective surveillance of <i>Mycobacterium tuberculosis</i> drug resistance in France 1995-2004. <i>European Respiratory Journal</i> , 2007, 30, 937-944.	6.7	28
132	Preemptive Isolation to Prevent Methicillin-Resistant <i>Staphylococcus aureus</i> Cross-Transmission in Diabetic Foot. <i>Diabetes Care</i> , 2007, 30, 2341-2342.	8.6	11
133	Orally Administered Combined Regimens for Treatment of <i>Mycobacterium ulcerans</i> Infection in Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 3737-3739.	3.2	57
134	Comparison of silver-impregnated with standard multi-lumen central venous catheters in critically ill patients*. <i>Critical Care Medicine</i> , 2007, 35, 1032-1039.	0.9	80
135	Type II topoisomerase mutations in clinical isolates of <i>Enterobacter cloacae</i> and other enterobacterial species harbouring the qnrA gene. <i>International Journal of Antimicrobial Agents</i> , 2007, 29, 402-409.	2.5	43
136	An intervention programme for the management of multidrug-resistant tuberculosis in France. <i>International Journal of Antimicrobial Agents</i> , 2007, 29, 434-439.	2.5	24
137	Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance) in 10 countries. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 59, 107-114.	13.7	294
138	Gentamicin-Susceptible or Gentamicin-Resistant Methicillin-Resistant <i>Staphylococcus aureus</i> A Case-Case Study. <i>Infection Control and Hospital Epidemiology</i> , 2006, 27, 879-883.	1.8	4
139	Implementation of isolation precautions: role of a targeted information flyer. <i>Journal of Hospital Infection</i> , 2006, 62, 163-165.	2.9	16
140	Occurrence of qnrA-positive clinical isolates in French teaching hospitals during 2002-2005. <i>Clinical Microbiology and Infection</i> , 2006, 12, 1013-1020.	6.0	56
141	An evaluation of data quality in a network for surveillance of <i>Mycobacterium tuberculosis</i> resistance to antituberculosis drugs in Ile-de-France region-2001-2002. <i>European Journal of Epidemiology</i> , 2006, 21, 783-785.	5.7	10
142	In Vitro and In Vivo Activities of Rifampin, Streptomycin, Amikacin, Moxifloxacin, R207910, Linezolid, and PA-824 against <i>Mycobacterium ulcerans</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 1921-1926.	3.2	100
143	Decreased susceptibility to glycopeptides in methicillin-resistant <i>Staphylococcus aureus</i> : a 20 year study in a large French teaching hospital, 1983-2002. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 57, 506-510.	3.0	83
144	Methicillin-resistant <i>Staphylococcus aureus</i> producing Panton-Valentine leukocidin in a retrospective case series from 12 French hospital laboratories, 2000-2003. <i>Clinical Microbiology and Infection</i> , 2005, 11, 585-587.	6.0	44

#	ARTICLE	IF	CITATIONS
145	Sentinel-site surveillance of Mycobacterium avium complex pulmonary disease. <i>European Respiratory Journal</i> , 2005, 26, 1092-1096.	6.7	33
146	Clinical features of Clostridium difficile-associated diarrhoea due to binary toxin (actin-specific) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 70.	1.8	184
147	Three-year survey of community-acquired methicillin-resistant Staphylococcus aureus producing Panton-Valentine leukocidin in a French university hospital. <i>Journal of Hospital Infection</i> , 2005, 61, 321-329.	2.9	45
148	Incidence of tuberculous meningitis in France, 2000: a capture-recapture analysis. <i>International Journal of Tuberculosis and Lung Disease</i> , 2005, 9, 803-8.	1.2	16
149	Diabetic foot ulcer and multidrug-resistant organisms: risk factors and impact. <i>Diabetic Medicine</i> , 2004, 21, 710-715.	2.3	167
150	Nosocomial infections and hospital mortality: a multicentre epidemiological study. <i>Journal of Hospital Infection</i> , 2004, 58, 268-275.	2.9	49
151	Preventing Central Venous Catheter-Associated Primary Bloodstream Infections: Characteristics of Practices Among Hospitals Participating in the Evaluation of Processes and Indicators in Infection Control (EPIC) Study. <i>Infection Control and Hospital Epidemiology</i> , 2003, 24, 926-935.	1.8	32
152	La multirésistance (MDR) de Mycobacterium tuberculosis aux antibiotiques en France depuis 1992. <i>Médecine Et Maladies Infectieuses</i> , 2003, 33, 183-187.	5.0	1
153	Comparison of US and non-US central venous catheter infection rates: Evaluation of processes and indicators in infection control study. <i>American Journal of Infection Control</i> , 2003, 31, 237-242.	2.3	12
154	Multidrug-resistant tuberculosis: eight years of surveillance in France. <i>European Respiratory Journal</i> , 2003, 22, 833-837.	6.7	40
155	Bactericidal Activity of Rifampin-Amikacin against Mycobacterium ulcerans in Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 3193-3196.	3.2	78
156	Sixty-three Cases of Mycobacterium marinum Infection. <i>Archives of Internal Medicine</i> , 2002, 162, 1746.	3.8	324
157	Lung Tissue Concentrations of Nebulized Amikacin during Mechanical Ventilation in Piglets with Healthy Lungs. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2002, 165, 171-175.	5.6	88
158	Outcomes of Primary and Catheter-related Bacteremia. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2001, 163, 1584-1590.	5.6	833
159	Global Trends in Resistance to Antituberculosis Drugs. <i>New England Journal of Medicine</i> , 2001, 344, 1294-1303.	27.0	567
160	Trends in quinolone susceptibility of Enterobacteriaceae among inpatients of a large university hospital: 1992-98. <i>Clinical Microbiology and Infection</i> , 2001, 7, 553-561.	6.0	17
161	Activities of New Macrolides and Fluoroquinolones against Mycobacterium ulcerans Infection in Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 3109-3112.	3.2	66
162	Efficacies of Clarithromycin Regimens against Mycobacterium xenopi in Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 3229-3230.	3.2	24

#	ARTICLE	IF	CITATIONS
163	Impact of Hospital Care on Incidence of Bloodstream Infection: The Evaluation of Processes and Indicators in Infection Control Study. <i>Emerging Infectious Diseases</i> , 2001, 7, 193-196.	4.3	18
164	Activities of Several Antimicrobials against <i>Mycobacterium ulcerans</i> Infection in Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 2367-2372.	3.2	69
165	The Influence of the Composition of the Nursing Staff on Primary Bloodstream Infection Rates in a Surgical Intensive Care Unit. <i>Infection Control and Hospital Epidemiology</i> , 2000, 21, 12-17.	1.8	219
166	Surveillance of <i>Mycobacterium tuberculosis</i> drug resistance in France, 1995-1997. AZAY Mycobacteria Study Group. <i>International Journal of Tuberculosis and Lung Disease</i> , 2000, 4, 665-72.	1.2	14
167	Outcome of Multi-drug-resistant Tuberculosis in France. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1999, 160, 587-593.	5.6	77
168	Type II Topoisomerase Mutations in Ciprofloxacin-Resistant Strains of <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 62-66.	3.2	120
169	Pacemaker Endocarditis Due to <i>Candida albicans</i> : Case Report and Review. <i>Clinical Infectious Diseases</i> , 1997, 25, 1359-1362.	5.8	35
170	Pharmacodynamics of antibiotics in fibrin clots. <i>Journal of Antimicrobial Chemotherapy</i> , 1993, 31, 113-136.	3.0	49
171	Reexpansion Pulmonary Edema Localized to a Lobe. <i>Chest</i> , 1989, 95, 1170.	0.8	2
172	SUBACUTE POLYNEUROPATHY WITH ENCEPHALOPATHY IN AIDS WITH HUMAN CYTOMEGALOVIRUS PATHOGENICITY?. <i>Lancet, The</i> , 1986, 328, 1039.	13.7	17
173	Randomised Trial to Compare Clarithromycin (Extended Release)-Rifampicin and Streptomycin-Rifampicin for Early, Limited Lesions of <i>M. Ulcerans</i> Infection. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0